Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT02415959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis

Interventions

DRUG: Creon IR
DRUG: Creon® (DR/GR)

Sponsor

Abbott

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]